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Smoking and non-alcoholic steatohepatitis (NASH):
The GREek Atorvastatin and Coronary heart
disease Evaluation (GREACE) trial
participated in advisory boards and trials sponsored by various
pharmaceutical companies (MSD, Genzyme, and Abbott).
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Letters to the Editor
Open access under CC BY-NC-ND license.To the Editor:
As the authors of the GREek Atorvastatin and Coronary heart dis-
ease Evaluation (GREACE) trial [1], we appreciate the comments
made by Babu et al. [2] and Zein et al. [3] regarding the role of
smoking on non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH). A few comments may be of
interest.
First, we assessed changes in vascular risk and the safety of
statins [1]. We could not analyse every possible relationship.
Second, in order to interpret the results of GREACE in terms of
NAFLD/NASH, there is a need to know how many patients were
smokers at the end of this trial. Essentially, the numbers were
similar to baseline values.
Third, it would be interesting to know the transaminase status
at the end of the GREACE study. In the NAFLD + not on statin
group, alanine aminotransferase (ALT) activity in smokers
(n = 19) was 70 ± 7 vs. 61 ± 9 U/L in non-smokers (n = 191),
p <0.0001. Therefore, smokers maintained a raised ALT activity
over the 3-year duration of the trial. In the NAFLD + on statin
group, ALT activity in smokers (n = 23) was 37 ± 6 vs. 37 ± 5 U/L
in non-smokers (n = 204), p = 0.10. This suggests that statins
improved ALT activity in smokers. These ﬁndings are limited
because they are based on a post hoc analysis and the number
of patients is small.
Our ﬁndings support the hypothesis discussed by Babu et al.
[2] and Zein et al. [3] regarding the adverse effect of smoking
on NAFLD and NASH. More work is needed in this ﬁeld.
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disease: Multiple mutations cause severe hepatic and
neurological complicationsTo the Editor:
Single kidney and liver cysts are common. If cysts occur multiply
and earlier in life, they are mostly inherited. Autosomal dominant
polycystic kidney disease (ADPKD) is one of the most common
genetic disorders with mutations in PKD1 or PKD2 and affects
10–15 million individuals worldwide [1]. Variable disease
expression even in the same family is incompletely understood,
some have intracranial aneurysms and most elderly patients
show liver cysts. Polycystic liver disease (ADPLD) is caused by a
dominant mutation in PRKCSH or SEC63, involved in posttransla-
tional translocation and quality control of proteins (such as the
ADPKD proteins) [2]. ADPLD patients can also harbour kidney476 Journal of Hepatology 2cysts. Morphologically, cysts are indistinguishable from those in
ADPKD. In mice, both diseases overlap not only clinically, but also
genetically and functionally, in line with a dosage-sensitive net-
work for polycystic liver and kidney disease [3].
We describe a family with liver and kidney cysts in which the
much more severely affected 39-year-old index patient (Fig. 1,
arrow) harbours a total of four mutant alleles in genes for PKD
and PLD, suggesting a dosage effect that may explain her severe
phenotype. Three aneurysms of the right middle cerebral artery
(MCA) led to subarachnoid haemorrhage at the age of 38 and
were surgically clipped. In addition, dissections of both carotid
arteries led to right-sided stenosis (Fig. 1). Massive liver disease012 vol. 57 j 467–477
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Fig. 1. Clinical and genetic data. (Top panel) Pedigree (arrow depicts proposita)
with information on the genotype of those family members from which a DNA
sample was analysed. All affected family members are shown in grey, whereas
the much more severely affected index patient is shown in black. (Middle panel)
Electropherograms of the mutations identiﬁed in the family’s index patient.
(Bottom left and middle panels) Abdominal CT of the family’s index patient
demonstrates lack of renal cysts, but extensive hepatomegaly with multiple liver
cysts and ascites that caused massive abdominal distention and will make a liver
transplantation soon necessary. (Bottom right panel) Right carotid angiography
(DSA) depicts internal carotid dissection with narrowing of the internal carotid
artery (ICA) just beneath the petrous part of that vessel. The dissection of the
patient’s left ICA and the aneurysms of the right middle cerebral artery are not
shown.
JOURNAL OF HEPATOLOGYwill require a transplantation soon, whereas, surprisingly, her
kidneys do not show any cyst despite homozygosity for the
known convincing non-conservative PKD1 mutation c.6749C >T
(p.T2250M) that affects an evolutionarily conserved amino acid
and that is bioinformatically predicted to be pathogenic [4].
Given her major hepatic cyst burden, we additionally sequenced
both ADPLD genes and identiﬁed two SEC63 mutations: pater-
nally, the novel truncating mutation c.133C >T (p.R45X), and
maternally, the non-conservative, an evolutionarily highly con-
served amino acid affecting mutation c.649C >T (p.R217C) which
has been described in ADPLD patients and is predicted to be path-
ogenic in silico [5]. All other affected family members with heter-
ozygosity for PKD1 and SEC63 only displayed a mild phenotype
with practically no disease burden and a few liver and kidney
cysts to varying degrees.
Elucidation of the molecular mechanisms that may explain
some of the phenotypic variability in families like ours is of
importance for the understanding of polycystic kidney and liver
disease. Reconstruction of our data by speciﬁc animal models
and functional assays would further corroborate our message,
but these experiments are cumbersome and considerably ham-
pered by the size and structure of PKD1. However, overall and
in line with the studies by Fedeles et al. and others [3,6], we think
that there is sufﬁcient evidence for a dosage-sensitive, tissue-Journal of Hepatology 20dependent network that may describe a general principle for
the modiﬁcation of disease expression and could have model
character for a variety of other disorders. Additional mutational
hits exert an aggravating effect and contribute to earlier and
more severe disease expression. It also underlines the importance
of proper trafﬁcking and quality control of proteins in human dis-
ease. Improved next-generation sequencing (NGS)-based facili-
ties will provide further rapidly growing insights into the
proposed mutational load theory and related issues. Our ﬁndings
contribute to the clinical and molecular understanding of poly-
cystic kidney and liver disease and the management of affected
families.12 vol. 57 j 467–477 477
